JNCCN 360 - CML - Ongoing CE Activities

Editors:

Gabriela S. Hobbs, MD

Michael J. Mauro, MD

Advertisement

Advertisement

Ongoing CE Activities

2019 Updates in Hematologic Malignancies and Disorders [log in required]

Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance to Refine Clinical Management Strategies

CAR-T Cell Therapy for Blood Cancer Patients

CHRONIC MYELOID LEUKEMIA: DIAGNOSIS, TREATMENT AND SIDE EFFECTS MANAGEMENT

Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICML

Clinical Updates in Chronic Myeloid Leukemia

Delivering Quality Care for Patients With CML: A Team Approach

Expert Guidance on Multidisciplinary Management of CAR T-Cell Toxicities

HEMATOLOGIC MALIGNANCIES IN CHILDREN: EARLY DIAGNOSIS AND MANAGEMENT

Highlights from the 3rd Annual Seminar Series on Hematologic Malignancies & Precision Medicine: An Expert Q&A

Key Studies in Leukemias: Independent Conference Coverage of ASH 2018

Minimal Residual Disease and Hematologic Malignancies: Why, How, in Whom, and When? [log in required]

New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia - Module - 2

Recorded Presentations From the NCCN 2019 Annual Congress: Hematologic Malignancies™

SUPPORTING OUR MYELOMA PATIENTS: TREATMENT, ACCESS BARRIERS & HIGH RISK PATIENTS

UNDERSTANDING CAR T-CELL THERAPY AS A TREATMENT OPTION FOR BLOOD CANCER PATIENTS

Sections

NCCN Resources

Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.